Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

G. Caocci, O. Mulas, I. Capodanno, E. Abruzzese, A. Iurlo, L. Luciano, F. Albano, M. Annunziata, M. Tiribelli, M. Bonifacio, S. Galimberti, F. Castagnetti, N. Sgherza, F. Stagno, A. Gozzini, E.M. Orlandi, D. Luzi, G. Binotto, P. Pregno, C. FozzaF. Efficace, M.P. Simula, M.M. Trawinska, D. Cattaneo, F. De Gregorio, I. Attolico, R. Stella, L. Scaffidi, C. Baratè, G. Gugliotta, E. Scalzulli, C. Elena, F. Pirillo, R. Foà, M. Breccia, G.L. Nasa

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalBlood Cancer J.
Volume10
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • cholesterol
  • high density lipoprotein
  • low density lipoprotein
  • ponatinib
  • triacylglycerol
  • adult
  • aged
  • artery occlusion
  • Article
  • cholesterol blood level
  • chronic myeloid leukemia
  • cohort analysis
  • drug withdrawal
  • dyslipidemia
  • female
  • human
  • Italian (citizen)
  • lipoprotein blood level
  • major clinical study
  • male
  • prognosis
  • risk reduction
  • triacylglycerol blood level

Cite this